New Dual-Action drug targets Hard-to-Treat tumors

NCT ID NCT06911489

Recruiting now Disease control Sponsor: Chengdu New Radiomedicine Technology Co. LTD. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug that can both image and treat advanced solid tumors. The drug targets a protein called FAP found on many cancer cells. The trial involves 132 adults with advanced solid tumors who have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the treatment can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR MALIGNANCY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Tianjin Medical University Cancer Insititute & Hospital
RECRUITING

Tianjin, China

Contact

Contact